@article {Caroline:2004:1175-0561:463,
author = "Caroline Fenton",
author = "Greg L. Plosker",
title = "Calcipotriol/Betamethasone Dipropionate: A Review of its Use in the Treatment of Psoriasis Vulgaris",
journal = "American Journal of Clinical Dermatology",
volume = "5",
year = "2004",
abstract = "The two-compound product containing calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g (Dovobet®, Daivobet®) [referred to here as calcipotriol/betamethasone dipropionate], is a topical treatment for psoriasis vulgaris, combining a vitamin D analog and a corticosteroid.For most adult patients with psoriasis vulgaris on the trunk and limbs, up to 4 weeks of therapy with calcipotriol/betamethasone dipropionate provides an effective and well tolerated treatment. In clinical trials, patients with a mean baseline psoriasis area and severity index (PASI) of 9.5–10.9 experienced a mean 65.0–74.4% PASI improvement within 4 weeks, significantly better than improvements with calcipotriol 50 µg/g monotherapy, betamethasone dipropionate 0.5 mg/g monotherapy, or placebo. In addition, in 6.4%–20.1% of patients, lesions cleared. In patients who were subsequently treated with calcipotriol maintenance therapy, benefits were retained for at least 4 weeks. The safety of calcipotriol/betamethasone dipropionate in patients treated for up to 1 year was generally good; fewer than 5% of patients experienced adverse events possibly associated with long-term corticosteroid use.",
pages = "463-478(16)",
url = "http://www.ingentaconnect.com/content/adis/derm/2004/00000005/00000006/art00012"
}